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Purpose: Recent studies have found that KRAS mutations predict resistance to monoclonal antibodies targeting the
epidermal growth factor receptor in metastatic colorectal cancer (mCRC). A polymorphism in a let-7 microRNA
complementary site (lcs6) in the KRAS 3# untranslated region (UTR) is associated with an increased cancer risk in
non-small-cell lung cancer and reduced overall survival (OS) in oral cancers. We tested the hypothesis whether this
polymorphism may be associated with clinical outcome in KRAS wild-type (KRASwt) mCRC patients treated with
cetuximab monotherapy.
Patients and methods: The presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who
were enrolled in a phase II study of cetuximab monotherapy (IMCL-0144). Genomic DNA was extracted from
dissected formalin-fixed paraffin-embedded tumor tissue, KRAS mutation status and polymorphism were assessed
using direct sequencing and PCR restriction fragment length polymorphism technique.
Results: KRAS let-7 lcs6 polymorphism was found to be related to object response rate (ORR) in mCRC patients
whose tumors had KRASwt. The 12 KRASwt patients harboring at least a variant G allele (TG or GG) had a 42% ORR
compared with a 9% ORR in 55 KRASwt patients with let-7 lcs6 TT genotype (P = 0.02, Fisher’s exact test). KRASwt
patients with TG/GG genotypes had trend of longer median progression-free survival (3.9 versus 1.3 months) and OS
(10.7 versus 6.4 months) compared to those with TT genotypes.
Conclusions: These results are the first to indicate that the KRAS 3’UTR polymorphism may predict for cetuximab
responsiveness in KRASwt mCRC patients, which warrants validation in other clinical trials.
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introduction
Colorectal cancer (CRC) remains the second leading cause of
cancer deaths in the United States. In 2009, an estimated 146
970 new cases will be diagnosed and 49 920 people will die from
this disease [1]. Cetuximab, an immunoglobulin G1
monoclonal antibody to the epidermal growth factor receptor
(EGFR), has demonstrated clinical efficacy as monotherapy and
when combined with chemotherapy in the treatment of
advanced disease [2–7].
Recently, KRAS mutation status has been demonstrated to be
a predictive marker of clinical benefit to monoclonal antibodies
targeting EGFR [8–11]. Although KRAS mutations, particularly
those involving codons 12 and 13 that are found in
approximately 30%–40% of patients with metastatic colorectal
cancer (mCRC), strongly relate to resistance to monoclonal
antibodies targeting EGFR, not all mCRC patients with KRASwt
derive benefit from these agents, and there is a need to identify
molecular markers that better identify which KRASwt mCRC
patients benefit from treatment. Previous studies had identified
additional markers in KRASwt patients that can better predict for
cetuximab responsiveness. For example, Jacobs et al. found that
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gene expression levels of two EGFR ligands, epiregulin and
amphiregulin (AREG) related to favorable outcome in 220
chemorefractory KRASwtmCRC patients treated with cetuximab
and irinotecan [12]. Several studies have demonstrated that high
EGFR gene copy number could be a predictive marker in CRC
patients treated with cetuximab [13, 14]. Furthermore, Laurent-
Puig et al. showed that BRAF status, cytoplasmic expression of
PTEN and EGFR amplification were associated with clinical
outcome in KRASwt patients treated with a cetuximab-based
regimen [15]. Finally, Sartore-Bianchi et al. pointed out that
PI3KCA mutations in CRC were associated with clinical
resistance to EGFR-targeted monoclonal antibodies including
cetuximab and panitumumab [16].
In addition to tumor characteristics playing an important role
in determining responsiveness to cetuximab, the genetic makeup
of patients may also contribute to determining cetuximab
sensitivity. Several studies have found that FccRIIa–FccRIIIa
polymorphisms, as well as COX-2 and EGFR germline
polymorphisms, are associated with clinical outcome in mCRC
patients treated with single-agent cetuximab independent of
KRAS status [17–19]. MicroRNAs are small, noncoding RNAs
that regulate gene expression by degrading and/or suppressing
the translation of target messenger RNA (mRNA) by base
pairing in the 3#-untranslated region (UTR) of mRNA [20].
Very recently, microRNA polymorphisms were discovered and
are becoming increasingly important in the fast growing field of
personalized medicine. MicroRNA polymorphisms could
present at or near a microRNA-binding site of functional genes.
MicroRNA polymorphisms can affect gene expression by
interfering with microRNA function. They have been shown to
affect drug response and have the potential to confer drug
resistance [21, 22]. The let-7 family of microRNAs were found to
regulate KRAS activity by binding to the 3#-UTR of human
KRAS gene [23]. Previous study demonstrated that a microRNA
polymorphism in the let-7 microRNA complementary-binding
site (lcs6) of the 3#UTR of KRAS gene was associated with
increased KRAS expression in in vitro model [24]. Furthermore,
this polymorphism was found to be associated with increased
cancer risk in non-small-cell lung cancer (NSCLC) patients and
reduced overall survival (OS) in oral cancers [24, 25], suggesting
functional and clinical significance.
Due to the important role of KRAS mutation status in
predicting cetuximab efficacy in CRC, we hypothesized that this
KRAS let-7 lcs6 polymorphism may predict efficacy of
cetuximab in KRASwt mCRC patients. We studied this
polymorphism in 130 mCRC patients who were refractory to
fluoropyrimidine, irinotecan, and oxaliplatin, and treated with
cetuximab as monotherapy in a phase II study (IMCL-0144).
patients and methods
patient characteristics and statistical analysis
One hundred and thirty (38%) of the 346 patients enrolled in IMCL-0144
had tumor tissues available and amenable for analysis of KRAS let-7 lcs6
polymorphism (Table 1). IMCL-0144 involved patients with
histopathologically confirmed mCRC, who were treated with cetuximab
monotherapy following failure of therapeutic regimens that included
fluoropyrimidine, irinotecan and oxaliplatin [26]. All 130 patients who had
available tumor tissue samples were included in the present
pharmacogenetic study, irrespective of clinical outcome and KRAS
mutation status. This study was performed at the University of Southern
California/Norris Comprehensive Cancer Center (USC/NCCC) following
approval by the Institutional Review Board of the University of Southern
California for Medical Sciences. All patients provided their written
informed consent for tissue collection to allow study of molecular
correlates.
The primary objective of this pharmacogenetic study was to evaluate
relationships between KRAS let-7 lcs6 polymorphism and tumor response in
KRASwt mCRC patients treated with single-agent cetuximab, whereas
secondary objectives included evaluations of relationships of the
polymorphism to progression-free survival (PFS) and OS. The PFS was
calculated from the time of the first date of cetuximab treatment until the first
observation of disease progression or death from any cause. If a patient had
not progressed or died, PFS was censored at the time of the last follow-up.
The OS time was calculated as the period from the first day of cetuximab
infusion or until death from any cause, at which the point data were censored.
The association of KRAS let-7 lcs6 polymorphism with tumor response
was determined by contingency table and the Fisher’s exact test. The
association between this polymorphism with OS and PFS was analyzed
using Kaplan–Meier plots and the log-rank test. The level of significance
was set to a P value of <0.05, and P values are given for -two-sided testing.
All statistical tests were performed using the SAS statistical package version
9.1 (SAS Institute Inc. Cary, NC), and Epilog Plus Version 1.0 (Epicentre
Software, Pasadena, CAc).
clinical evaluation of response criteria
Objective tumor response was assessed every 6 weeks during the course of
the study and criteria were based on modified World Health Organisation
guidelines [26]. Response to cetuximab was determined by an independent
response assessment committee that was blinded to the investigator-
reported measurements and assessments were reported in the study. A
partial response required at least a 50% reduction in the sum of the
bidimensional products of all measurable lesions documented at least 4
weeks apart. Treatment was continued in the absence of intolerable toxicity
Table 1. Pretreatment characteristics among patients whose specimens
available for genotyping in IMCL-0144
Single-agent cetuximab (n = 130)
Frequency %
Median age, year (range) 60 (29–85)
Sex
Female 66 51
Male 64 49
Race
Caucasian 121 93
African-American 3 2
Asian 3 2
Other 3 2
ECOG performance status
0 52 41
1 76 59
2 0 0
KRAS mutation status*
(*Codons 12 and 13)
Wild-type 88 68
Mutant 42 32
ECOG, Eastern Cooperative Oncology Group.
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or progressive disease, defined as at least a 25% increase in measurable
disease, unequivocal growth of existing nonmeasurable disease, the
appearance of one or more new lesions or reappearance of old lesions.
KRAS mutation status and KRAS let-7 lcs6 genotyping
Tissue specimens from primary tumors were collected and genomic DNA was
extracted using the QIAamp kit (Qiagen, CA). KRAS mutation status was
determined by direct sequencing as previously described [17]. Briefly,
microdissected tumor DNA was amplified using following primer set: forward:
5#-TGA CTG AAT ATA AAC TTG TGG TAG TTG -3#, and reverse: 5#-TCG
TCC ACA AAA TGA TTC TGA A-3#. PCR fragments were sequenced on an
ABI 3100A Capillary Genetic Analyzer (Applied Biosystems), and analyzed in
both sense and antisense directions for the presence of heterozygous mutations.
Analysis of the DNA sequence was performed using ABI Sequencing Scanner
v1.0 (Applied Biosystems). KRAS let-7 lcs6 polymorphism (rs61764370) was
tested using PCR restriction fragment length polymorphism (PCR-RFLP)
technique. Briefly, forward primer 5#-TTA GGA GAG ACG GGG TTT CA-3#
and reverse primer 5#-AAA TGA GTT CTG CAA AAC AGG-3# were used for
PCR amplification, PCR products were digested by restriction enzyme TfiI
(New England Biolab, MA), and alleles were separated on 4% NuSieve
ethidium bromide-stained agarose gel.
results
The 130 patients whose tissues samples were available for
pharmacogenomic and molecular analyses in the present study
had a similar median PFS (1.3 months), OS (6.3 months), and
ORR (9.2%) values compared with patients whose tissues
samples were not available for assessment in the present study
(n = 216); the respective median values were PFS 1.5 months,
OS 6.8 months, and ORR 13%, respectively [26].
Analysis of KRAS let-7 lcs6 polymorphism was available in
111 patients due to exhaustion of available DNA from previous
diagnostic testing. Thirteen of 111 patients (12%) were not
assessable for tumor response. In 98 patients assessable for
tumor response, 67 patients had wild-type KRAS and 31
patients had mutant KRAS. None of the 31 patients with
a documented KRAS mutation responded to cetuximab,
whereas 10 of the 67 KRASwt patients responded (0% versus
15%, respectively; P = 0.01, Fisher’s exact test). In the 111
patients assessable for PFS and OS, KRASwt patients had
significantly longer PFS (P = 0.023) and OS (P = 0.02) values
compared with KRAS-mutated patients. Fifty-five (82%) of the
67 KRASwt patients had the KRAS let-7 lcs6 TT genotype.
There are 12 KRASwt patients harboring at least one let-7 lcs6
variant G allele (TG or GG). These 12 patients had a 42% (5/
12) ORR compared with 55 KRASwt patients with wild-type TT
genotype who had a 9% (5/55) ORR (P = 0.02, Fisher’s exact
test; Figure 1). None of the 31 KRAS mutant patients had an
objective response to cetuximab regardless of KRAS let-7 lcs6
polymorphism. Of the 28 KRASmutant patients with KRAS let-
7 lcs6 TT genotype, 10 had stable disease and 18 had
progressive disease as their best response, whereas all 3 patients
whose tumors had KRASmutations and had a heterozygous TG
genotype had progressive disease as their best response. There
were no statistically significant associations between KRAS let-7
lcs6 polymorphism and OS, PFS either in wild-type or in
mutant KRAS patients (Table 2). KRASwt patients who
possessed a TT genotype (n = 62) had a median PFS of 1.3
months (95%CI: 1.2–1.5 months) compared with patients
with at least one variant allele (TG or GG; n = 13) who had
a median PFS of 3.9 months (95% CI: 1.2–5.5 months; P =
0.25, log-rank test). The median OS for KRASwt patients with
a TT genotype was 6.4 months (95%CI: 3.6–8.2 months)
compared with 10.7 months (95% CI: 5.5–12.7 months) for
those harboring at least one variant allele (P = 0.33, log-rank
test; Figures 2 and 3).
discussion
Our data have shown for the first time that a KRAS let-7
microRNA-binding site polymorphism (lcs6) in the 3#-UTR of
the KRAS gene relates to tumor response in KRASwt mCRC
patients treated with cetuximab monotherapy. Although
patient numbers are small, our preliminary data demonstrated
that KRASwt patients with KRAS let-7 lcs6 TT genotype had
worse ORR compared with those with TG/GG genotype. The
12 KRASwt patients harboring at least a variant G allele (TG or
GG) had a 42% ORR compared with 55 KRASwt patients who
possessed wild-type TT genotype with only 9% ORR (P = 0.02,
Fisher’s exact test). Patients with TG/GG allele had a longer PFS
and OS but did not reach statistical significance due to the
small sample size.
MicroRNA polymorphisms are emerging as significant
molecular markers in the field of personalized medicine. They
have been shown to affect drug response and are reported to be
associated with many diseases including cancer. KRAS let-7 lcs6
microRNA polymorphism has been shown to be associated
with oral cancer survival and lung cancer risk in different
studies [24]. Christensen et al. examined the let-7 lcs6
polymorphism and the association with disease occurrence and
OS in a population-based case–control study of patients with
squamous cell carcinoma of the head and neck (HNSCC). Their
results suggest that HNSCC patients who carry the KRAS let-7
lcs6 variant allele have a significantly reduced OS compared
with patients with a let-7 lcs6 wild-type TT genotype [25].
Meanwhile, Chin et al. evaluated the same let-7 lcs6
polymorphism and its relationship with the risk of developing
NSCLC. Their data have shown that the lcs6 variant allele in
a KRAS microRNA complementary site is significantly
Figure 1. Tumor response by KRAS let-7 lcs6 polymorphism in KRASwt
patients enrolled in IMCL-0144.
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associated with increased risk for NSCLC among those with
a moderate smoking history [24].
Recent studies have shown that KRAS is regulated by the let-
7 microRNA family. The 3#-UTR region of the human KRAS
genes contains multiple let-7 complementary sites (lcs),
allowing let-7 to regulate KRAS activity [23]. In CRC,
transfection of cell lines with a let-7a-1 precursor microRNA
resulted in growth suppression and a decrease in KRAS protein
levels, suggesting that let-7 microRNA may play a role in
suppressing colon cancer growth [27]. Moreover, it have been
demonstrated that let-7 microRNA is not only involved in the
growth of colon cancer cells, but can also modulate tumor
sensitivity to chemotherapeutic agents [28]. Nakajima et al.
have shown an association for members of the let-7 family of
microRNAs with responsiveness to the oral fluoroyprimidine S-
1. They found the level of expression of let-7g strongly related
to responsiveness to S-1 treatment in 46 patients with recurrent
or refractory advanced CRC [28].
These findings suggest that patients with KRASwt CRCs who
also carry a variant KRAS let-7 lcs6 allele have a higher
probability of responding to cetuximab monotherapy
compared with those with wild-type TT genotype. However,
these results were derived retrospectively and involve
a relatively small number of patients, and therefore should be
Figure 3. Progression-free survival by KRAS let-7 lcs6 polymorphism in KRASwt patients treated with cetuximab monotherapy.
Figure 2. Overall survival by KRAS let-7 lcs6 polymorphism in KRASwt patients treated with cetuximab monotherapy.
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considered hypothesis generating and subject to confirmation
in prospective and randomized controlled studies. Surprisingly,
these findings that are opposite to our hypothesis that the
variant let-7 lcs6 allele has been associated with lower let-7
levels and increased KRAS expression in NSCLC patients
compared with the wild-type allele leads to greater activation of
Ras/MAPK pathway, which is a known mechanism of resistance
to anti-EGFR monoclonal antibodies [24]. One possible
explanation for our finding is colon cancer patients whose
tumors harbor the variant lcs6 allele may also have increased
KRAS expression and activity, resulting in increased tumoral
oncogenic addiction in the presence of EGFR signaling. As
KRAS is a key mediator of the EGFR signal transduction
primarily via the MAPK pathway, it seems plausible that
patients with increased tumoral KRAS expression as a result of
the lcs6 variant allele, may demonstrate increased sensitivity to
the suppression of this increased oncogenic signaling by
cetuximab treatment. As these tumors are KRASwt, cetuximab
treatment will suppress EGFR tyrosine kinase phosphorylation
reverting KRAS to its inactive GDP state, and the rapid loss of
prosurvival signals and the simultaneous increase in
proapoptotic signals may commit the cell to apoptotic death.
This provides a plausible explanation as to why patients
harboring the variant KRAS let-7 lcs6 polymorphism
demonstrate a superior response to cetuximab. Similar
observations were found in NSCLC patients treated with the
EGFR tyrosine kinase inhibitor (TKI) gefitinib [29]. Weiss et al.
showed microRNA-128b negatively regulates EGFR by binding
to the EGFR 3#-UTR. In their lung cancer cell line and
clinical specimen analyses, they found a loss of microRNA-128b
related to increased EGFR expression and responsiveness to
treatment with EGFR TKIs [29]. Furthermore, in vitro and in
vivo studies are needed to explore the possible mechanism
between this let-7 lcs6 polymorphism and cetuximab efficacy.
In summary, this study supports the role of let-7 lcs6
polymorphisms as a predictive marker of cetuximab efficacy in
patients with KRASwt mCRC treated with cetuximab as
monotherapy. Due to the retrospective nature of this study,
these results should be interpreted carefully. Prospective,
randomized controlled and biomarker embedded clinical trials
are needed to confirm and validate our findings.
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